This site is intended for health professionals only

EMA consults on excipient labelling

teaser

The European Medicines Agency (EMA) has published a new consultation paper on the need for revision of the guideline on excipients in the label and package leaflet of medicinal products for human use. 

 

The EMA are concerned that their current guidelines in this area do not sufficiently address the paediatric population or pregnant women. 

 

The concept guideline states: “

It is important to note that the safety of excipients can affect children differently than adults due to the ongoing organ development and incomplete maturation depending on the age.”

 

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

Regarding pregnant women, the concept guideline says: “

Safety labelling is needed for products intended for use in this population to ensure the safety of the unborn child(ren).”

 

The EMA also suggest that a revised guideline cover additional routes of administration and excipients, and give more information about how warnings in the package leaflet should be addressed in the summary of product characteristics (SmPC). 

 

Hospital Pharmacists can return their views on EMA’s concept paper by 31 May 2012.

 

European Medicines Agency






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x